Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis

Introduction: In Chinese patients with NSCLC, prevalence of EGFR-mutated (EGFRm) disease is high. In the global phase 3 ADAURA study (NCT02511106), adjuvant osimertinib was found to have a statistically significant and clinically meaningful improvement in disease-free survival (DFS) versus placebo i...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Jie Wang, MD, PhD, Yi-Long Wu, MD, Shun Lu, MD, PhD, Qun Wang, MD, Shanqing Li, MD, Wen-Zhao Zhong, MD, PhD, Qiming Wang, MD, Wei Li, MD, PhD, Buhai Wang, MD, Jun Chen, MD, Ying Cheng, MD, Hongbing Duan, MD, Gaofeng Li, MD, Li Shan, MD, Yangbo Liu, MS, Jing Liu, MD, Xiangning Huang, PhD, Ana Bolanos, MD, Jie He, MD, PhD
Format:	Artigo
Sprog:	Inglês
Udgivet:	Elsevier 2024-02-01
Serier:	JTO Clinical and Research Reports
Fag:	Adjuvant Osimertinib EGFR NSCLC China
Online adgang:	http://www.sciencedirect.com/science/article/pii/S2666364323001649
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!